Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Trulicity Summary of Product Characteristics (SmPC)

Trulicity® (dulaglutide): Long-term Safety

Both dulaglutide 1.5 mg and dulaglutide 0.75 mg treatment doses reported more treatment-emergent adverse events than the sitagliptin treatment group

Detailed Information

The AWARD-5 study was an adaptive, multicenter, randomized, 104-week, double-blind study that compared once-weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg treatments with once-daily sitagliptin 100 mg and placebo in patients with T2DM inadequately controlled with metformin.1,2

Treatment with dulaglutide was associated with a significantly higher incidence of GI TEAEs than treatment with sitagliptin (p<.05).1,2

Nausea, diarrhea, and vomiting were the most commonly reported AEs with the incidence highest after 2 weeks of treatment and decreased at the following visits.1

Both dulaglutide 1.5 mg and dulaglutide 0.75 mg treatment doses reported more TEAEs than the sitagliptin treatment group due to greater incidence of GI AEs (Table 1).1

A similar incidence of serious AEs was reported across treatment groups (Table 1).1

Table 1. Adverse Events From Baseline to 104 Weeks in Patients Treated With Dulaglutide 1.5 mg, Dulaglutide 0.75 mg, or Sitagliptin 100 mg in the AWARD-5 Study 1,3

Variablea

DULA 1.5 mg
n=304

DULA 0.75 mg
n=302

SITA 100 mg
n=315

Treatment-emergent adverse events ≥1

259 (85)

255 (84)

242 (77)

Treatment-emergent GI adverse events

    Nausea

53 (17)

44 (15)

21 (7)

    Vomiting

41 (14)

25 (8)

11 (4)

    Diarrhea

49 (16)

36 (12)

18 (6)

    Abdominal pain

21 (7)

13 (4)

11 (4)

    Abdominal distention

13 (4)

15 (5)

3 (1)

    Dyspepsia

18 (6)

19 (6)

14 (4)

Pancreatic enzymes, median (Q1,Q3) [U/I]

    Lipase

6 (-1,14)

6 (-1,18)

3 (-2,9)

    Total amylase

6 (-1,15)

7 (-1,17)

3 (-3,12)

    p-Amylase

4 (0,9)

4 (0,11)

2 (-1,7)

Pancreatitis

0 (0) 

0 (0) 

2 (0.6)

Serious adverse events

36 (12)

23 (8)

32 (10)

    Infections and infestations

7 (2)

3 (1)

5 (2)

    Cardiac disorders

6 (2)

2 (1)

4 (1)

    Neoplasms

5 (2)

3 (1)

5 (2)

    Gastrointestinal events

4 (1)

2 (1)

4 (1)

    Renal/urinary disorders

5 (2)

2 (1)

0 (0)

Death

1 (<1)

0 (0)

2 (1)

Injection site reactions

4 (1.3)

3 (1.0)

3 (1.0)

Hypoglycemiab, mean (SD)

    Total

0.0 (0.2)

0.0 (0.5)

0.0 (0.3)

    Documented symptomatic

0.0 (0.1)

0.0 (0.5)

0.0 (0.3)

Discontinuation resulting from adverse events

63 (21)

64 (21)

65 (21)

Vital signs, LSM (SE)

    Systolic blood pressure, mmHg

-0.1 (0.8)

1.3 (0.8)

<0.1 (0.8)

    Diastolic blood pressure, mmHg

0.4 (0.5)

1.4 (0.5)

-0.4 (0.5)

    Pulse rate, beats/min

2.3 (0.5)

2.8 (0.5)

-0.8 (0.5)

Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; DULA = dulagultide; GI = Gastrointestinal; LSM = least squares mean; Q1 = first quartile; Q3 = third quartile; SITA = Sitagliptin; U/l = units per liter.

a Data presented as n (%) unless otherwise indicated.

b <54 mg/dL cutoff, 1-year adjusted rate.

  

References

1. Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849-858. http://dx.doi.org/10.1111/dom.12479

2. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149-2158. http://dx.doi.org/10.2337/dc13-2761

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

AE = adverse event

AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes

GI = gastrointestinal

T2DM = type 2 diabetes mellitus

TEAE = treatment-emergent adverse event

Date of Last Review: January 06, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request